| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 141.1 | 134.2 |
| Gross profit | 99.9 | 75.6 |
| Profit before tax | 65.6 | 47.5 |
| Net income | 49.9 | 36.4 |
| EPS (diluted, $ a share) | $0.22 | $0.15 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +36.9% |
|---|---|
| Revenue, year on year | +5.1% |
| Gross margin | 70.8% |
| Operating margin | 48.0% |
10-Q filed with the SEC, NASDAQ: ADMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Adma Biologics, Inc.: key numbers
- Share price
- $13.63Close, Nov 17
- Market cap
- $3.02B
- Shares outstanding
- 221.85MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Adma Biologics, Inc.
All →Adma Biologics Director Lawrence P. Guiheen Sells $139K of Stock
Lawrence P. Guiheen, Director, sold 10,000 shares of Adma Biologics, Inc. at $13.92 a share, worth $139K in total on Nov 16, 2026. Shares held after the trade: 63,599 (-13.6%).
- Value
- $139K
- Shares
- 10,000
- Price
- $13.92
- Role
- Director
- Holding change
- -13.6%
- Trade date
- Nov 16, 2026
Adma Biologics President and CEO Adam S. Grossman Sells $288K of Stock
Adam S. Grossman, President and CEO, sold 21,000 shares of Adma Biologics, Inc. at $13.72 a share, worth $288K in total on Nov 16, 2026. Shares held after the trade: 2,064,777 (-0.3%).
- Value
- $288K
- Shares
- 21,000
- Average price
- $13.72
- Role
- President and CEO
- Holding change
- -0.3%
- Trade date
- Nov 16, 2026
Adma Biologics President and CEO Adam S. Grossman Sells $1.76M of Stock
Adam S. Grossman, President and CEO, sold 147,000 shares of Adma Biologics, Inc. at $12.00 a share, worth $1.76M in total on Nov 5, 2026. Shares held after the trade: 2,070,777 (-2.0%).
- Value
- $1.76M
- Shares
- 147,000
- Average price
- $12.00
- Role
- President and CEO
- Holding change
- -2.0%
- Trade date
- Nov 5, 2026
Adma Biologics Financial Results
ADMA Biologics reported third quarter 2026 financial results, highlighted by a 5% year-over-year increase in total revenue to $141.1 million and a 37% increase in GAAP net income to $49.9 million. The growth was primarily driven by ASCENIV revenue, which rose 31% to $124.7 million due to expanding physician adoption and patient starts. The company reiterated its full-year 2026 revenue guidance of at least $530 million while increasing its adjusted earnings outlook.
- Term
- 3 months ended September 30, 2026
“Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth. ASCENIV revenue increased 31% year-over-year, driven by expanding physician adoption, new patient starts and growing end-user utilization.”
Adam Grossman, President and Chief Executive Officer
“Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immunodeficiency patients and supports growing commercial adoption. With our yield-enhanced manufacturing capabilities, robust cash generation and disciplined capital allocation, we believe ADMA is well positioned to deliver sustained, profitable growth and long-term stockholder value creation.”
Adam Grossman, President and Chief Executive Officer